Online first
Wytyczne / stanowisko ekspertów
Opublikowany online: 2024-05-06
Wyświetlenia strony 42
Wyświetlenia/pobrania artykułu 4
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Stanowisko ekspertów dotyczące diagnostyki i leczenia olaparybem nowotworów BRCA-zależnych

Artur Kowalik12, Anita Chudecka-Głaz3, Joanna Kufel-Grabowska4, Iwona Skoneczna5, Tomasz Kubiatowski56

Streszczenie

Produkty białkowe genów BRCA1 i BRCA2 odgrywają kluczową rolę w procesach naprawy DNA, realizowanych na drodze rekombinacji homologicznej. Utrzymanie prawidłowej struktury dwuniciowego DNA jest kluczowe dla stabilności genomu i zapobiegania procesom transformacji nowotworowej, w tym niekontrolowanej proliferacji komórek nowotworowych. Ponadto białko BRCA1 odgrywa ważną rolę w regulacji cyklu komórkowego i ekspresji genów, w tym tych odpowiedzialnych za poszczególne fazy cyklu komórkowego, oraz remodelowaniu chromatyny. Białko BRCA2 uczestniczy natomiast w modulowaniu odpowiedzi immunologicznej, włączając tę indukowaną obecnością antygenów nowotworowych. Mutacje germinalne lub somatyczne w genach BRCA1 i BRCA2 występują w wielu nowotworach, między innymi u chorych ze zdiagnozowanym rakiem piersi, jajnika, prostaty czy trzustki. Ich wykrycie jest ważnym czynnikiem prognostycznym odpowiedzi na chemioterapię opartą na pochodnych platyny lub inhibitorach polimerazy poli-ADP rybozy (PARP). W niniejszym artykule omówiono najważniejsze aspekty diagnostyki molekularnej oraz wskazania do stosowania olaparybu w leczeniu chorych na raka piersi, jajnika, prostaty czy trzustki.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 95,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010; 28(22): 3570–3576.
  2. Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin Oncol. 2017; 44(3): 187–197.
  3. Grafodatskaya D, O'Rielly DD, Bedard K, et al. Practice guidelines for tumour testing in ovarian cancer. J Med Genet. 2022; 59(8): 727–736.
  4. van Dijk EL, Jaszczyszyn Y, Thermes C. Library preparation methods for next-generation sequencing: tone down the bias. Exp Cell Res. 2014; 322(1): 12–20.
  5. Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018; 379(18): 1754–1765.
  6. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019; 16(7): 409–424.
  7. Kowalik A, Kowalewska M, Góźdź S. Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. Transl Res. 2017; 185: 58–84.e15.
  8. Chandrasekaran D, Sobocan M, Blyuss O, et al. Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. Cancers (Basel). 2021; 13(17).
  9. Kowalik A, Zalewski K, Kopczyński J, et al. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Pol J Pathol. 2019; 70(2): 115–126.
  10. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20(3): 764–775.
  11. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21): 2654–2663.
  12. Mavaddat N, Barrowdale D, Andrulis I, et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 134–147.
  13. Wen H, Feng Z, Ma Y, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. BMC Cancer. 2022; 22(1): 550.
  14. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020; 31(12): 1606–1622.
  15. Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017; 23(4): 517–525.
  16. Winter C, Nilsson MP, Olsson E, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016; 27(8): 1532–1538.
  17. Kowalik A, Siołek M, Kopczyński J, et al. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study. PLoS One. 2018; 13(7): e0201086.
  18. Wojcik P, Jasiowka M, Strycharz E, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016; 14: 5.
  19. Gonzalez D, Mateo J, Stenzinger A, et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021; 7(4): 311–325.
  20. Chi KN, Barnicle A, Sibilla C, et al. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res. 2023; 29(1): 81–91.
  21. Matsubara N, de Bono J, Olmos D, et al. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. Clin Cancer Res. 2023; 29(1): 92–99.
  22. Hiemenz MC, Graf RP, Schiavone K, et al. Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens. Oncologist. 2022; 27(12): e970–e972.
  23. Wong W, Raufi AG, Safyan RA, et al. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020; 12: 2731–2742.
  24. Vietri MT, D'Elia G, Caliendo G, et al. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation. Genes (Basel). 2022; 13(2).
  25. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7–34.
  26. Lisio MA, Fu L, Goyeneche A, et al. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci. 2019; 20(4).
  27. Control U. Epithelial ovarian cancer. Rev Cancer Med WHO Lists Essent Med. 2014; 42(2010): 1–9.
  28. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012; 124(2): 347–353.
  29. King MC, Marks JH, Mandell JB, et al. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645): 643–646.
  30. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11): 1329–1333.
  31. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997; 60(3): 496–504.
  32. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68(3): 700–710.
  33. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104(12): 2807–2816.
  34. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353): 609–615.
  35. Bowtell DDL. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010; 10(11): 803–808.
  36. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012; 107(10): 1776–1782.
  37. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009; 40(9): 1213–1223.
  38. Piek JMJ, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003; 2(2): 73–78.
  39. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 2002; 94(1): 61–67.
  40. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002; 94(18): 1396–1406.
  41. Lim SL, Smith P, Syed N, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer. 2008; 98(8): 1452–1456.
  42. Wang Z, Li M, Lu S, et al. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 2006; 5(3): 256–260.
  43. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle. 2003; 2(4): 290–292.
  44. Soegaard M, Kjaer SK, Cox M, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008; 14(12): 3761–3767.
  45. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002; 21(4): 407–411.
  46. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011; 22(6): 1346–1352.
  47. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011; 22(5): 1127–1132.
  48. Gourley C, Michie CO, Roxburgh P, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010; 28(15): 2505–2511.
  49. Hyman DM, Zhou Q, Iasonos A, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 2012; 118(15): 3703–3709.
  50. Bolton KL, Chenevix-Trench G, Goh C, et al. EMBRACE, kConFab Investigators, Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4): 382–390.
  51. Liu J, Cristea MC, Frankel P, et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012; 205(1-2): 34–41.
  52. Reitsma W, de Bock GH, Oosterwijk JC, et al. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different? Int J Gynecol Cancer. 2012; 22(4): 579–585.
  53. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003; 97(9): 2187–2195.
  54. Lacour RA, Westin SN, Meyer LA, et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011; 121(2): 358–363.
  55. Pal T, Permuth-Wey J, Kapoor R, et al. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007; 6(1): 113–119.
  56. Pharoah PD, Easton DF, Stockton DL, et al. Survival in familial, BRCA1- associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for earch (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999; 59(4): 868–871.
  57. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008; 26(1): 20–25.
  58. Yang Da, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14): 1557–1565.
  59. DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival at 7-year follow up in patients with newly diagnosed advanced ovarian cancer and BRCA mutation who received maintenance Olaparib in the SOLO1/GOG 3004 trial. ESMO Congress Paris, 2022.
  60. Ray-Coquard IL, Leary A, Pignata S, et al. Final overall survival results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance Olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. ESMO Congress Paris, 2022.
  61. Tew WP, Lacchetti C, Kohn EC, et al. PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020; 38(30): 3468–3493.
  62. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26): 2495–2505.
  63. Bradley W, Moore K, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. Gynecol Oncol. 2021; 162: S25–S26.
  64. Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5). Gynecol Oncol. 2022; 166: S50–S51.
  65. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25): 2403–2415.
  66. Ray-Coquard I, Pautier P, Pignata S, et al. PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25): 2416–2428.
  67. Monk BJ, Parkinson C, Lim MC, et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022; 40(34): 3952–3964.
  68. Gonzalez-Martin A, Harter A, Leary D, et al. Newly diagnose and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow up. Annnc2023.07.011.
  69. Vergote I, González-Martín A, Ray-Coquard I, et al. European experts’ consensus group. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022; 33(3): 276–287.
  70. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15(8): 852–861.
  71. Pujade-Lauraine E, Ledermann JA, Selle FI, et al. Olaprib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21); a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1274–1284.
  72. Poveda A, Floquet A, Ledermann JA, et al. SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(5): 620–631.
  73. Budny A, Starosławska E, Budny B, et al. [Epidemiology and diagnosis of breast cancer]. Pol Merkur Lekarski. 2019; 46(275): 195–204.
  74. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. BRCA1 and BRCA2 Cohort Consortium. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23): 2402–2416.
  75. Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021; 16(3): 255–282.
  76. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(8): 1194–1220; Erratum in: Ann Oncol. 2021;32(2): 284.
  77. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
  78. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379(8): 753–763.
  79. Tutt ANJ, Garber JE, Kaufman B, et al. OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. N Engl J Med. 2021; 384(25): 2394–2405.
  80. Geyer CE, Garber JE, Gelber RD, et al. OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022; 33(12): 1250–1268.
  81. Abeshouse A, Ahn J, Akbani R, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163(4): 1011–1025.
  82. Robinson D, Van Allen E, Wu YM, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015; 161(5): 1215–1228.
  83. NCCN Guidelines Prostate Cancer Early Detection ver. 1.2023, Prostate Cancer ver. 3.2023.
  84. Herberts C, Wyatt AW, Nguyen PL, et al. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. Am Soc Clin Oncol Educ Book. 2023; 43: e390384.
  85. Taneja SS. Re: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Urol. 2013; 190(6): 2093.
  86. Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2015; 68(2): 186–193.
  87. Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015; 373(18): 1697–1708.
  88. Bono Jde, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(22): 2091–2102.
  89. Hussain M, Mateo J, Fizazi K, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24): 2345–2357.
  90. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022; 1(9): EVIDoa2200043.
  91. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10398): 291–303.
  92. Chi K, Rathkopf D, Smith M, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023; 41(18): 3339–3351.
  93. Chi J, Chung SuY, Parakrama R, et al. The role of PARP inhibitors in mutated pancreatic cancer. Therap Adv Gastroenterol. 2021; 14: 17562848211014818.
  94. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016; 16(2): 110–120.
  95. Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018; 319(23): 2401–2409.
  96. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(2): 342–346.
  97. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014; 111(6): 1132–1138.
  98. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4): 317–327.
  99. Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022; 40(34): 3929–3939.
  100. Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021; 39(3_suppl): 378–378.



Onkologia w Praktyce Klinicznej - Edukacja